4D Molecular Therapeutics (FDMT) Total Non-Current Liabilities (2019 - 2026)

4D Molecular Therapeutics (FDMT) has reported Total Non-Current Liabilities for 8 consecutive years, with $60.9 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Total Non-Current Liabilities rose 32.99% year-over-year to $60.9 million; the TTM figure through Mar 2026 stood at $60.9 million (up 32.99% YoY), while the FY2025 annual figure was $60.9 million, up 22.84% from the prior year.
• Total Non-Current Liabilities steadied at $60.9 million in Q1 2026 per FDMT's latest filing, from $60.9 million in the prior quarter.
• Across five years, Total Non-Current Liabilities topped out at $60.9 million in Q1 2026 and bottomed at $25.4 million in Q1 2023.
• Historically, Total Non-Current Liabilities has averaged $39.4 million across 5 years, with a median of $31.7 million in 2023.
• Annual changes were most pronounced in 2022 — Total Non-Current Liabilities jumped 144.84% — and 2023, when it decreased 12.02%.
• 4D Molecular Therapeutics' Total Non-Current Liabilities stood at $30.5 million in 2022, then gained by 3.95% to $31.7 million in 2023, then surged by 56.45% to $49.6 million in 2024, then grew by 22.84% to $60.9 million in 2025, then gained by 0.06% to $60.9 million in 2026.
• Business Quant data shows FDMT's Total Non-Current Liabilities at $60.9 million in Q1 2026, $60.9 million in Q4 2025, and $54.7 million in Q3 2025.